Source
Author: unknown
Eli Lilly to buy genetic medicine developer Akouos for $487 million [Deals Market Headlines | Breaking Stock Market News | Reuters]
Related Posts
Bain Capital Nears $2.6 Billion HealthEdge Acquisition in Strategic Healthcare Tech Expansion
Private equity heavyweight Bain Capital is finalizing a $2.6 billion acquisition of healthcare technology leader HealthEdge Software from Blackstone Group, according to multiple sources familiar...
Eli Lilly’s Potential Acquisition of Scorpion Therapeutics: A Strategic Shift Amid Market Volatility
Strategic Acquisition: Eli Lilly's potential acquisition of Scorpion Therapeutics signals a strategic move to bolster its oncology pipeline and enhance innovation capabilities. Biotech Market...
Biogen Bids for Sage Therapeutics: Boosting Neuroscience & Psychiatric Treatments
Strategic Rationale: Biogen's bid to acquire Sage Therapeutics' remaining stake aligns with its long-term strategy to expand neuroscience capabilities and strengthen its psychiatric and neurological...
GSK Acquires IDRx for $1.15B: A Precision Leap in GI Cancer Therapy
Strategic Expansion: GSK's $1.15B acquisition of IDRx bolsters its gastrointestinal (GI) cancer therapy portfolio, marking a significant expansion into the oncology market. Financial Details: The...